MX2020010871A - Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia. - Google Patents
Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.Info
- Publication number
- MX2020010871A MX2020010871A MX2020010871A MX2020010871A MX2020010871A MX 2020010871 A MX2020010871 A MX 2020010871A MX 2020010871 A MX2020010871 A MX 2020010871A MX 2020010871 A MX2020010871 A MX 2020010871A MX 2020010871 A MX2020010871 A MX 2020010871A
- Authority
- MX
- Mexico
- Prior art keywords
- rna
- cap
- therapy
- cells
- trinucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a compuestos de 5'-caperuza, en particular la estabilización de ARN por estos compuestos de 5'-caperuza, y proporciona composiciones, tal como composiciones farmacéuticas, y células que comprende un ARN que se modifica con este compuesto de 5'-caperuza, así como métodos para producir un péptido o proteína de interés usando la composiciones o células de acuerdo con la presente invención. Además, la presente invención proporciona el ARN, composiciones, o células para el uso en la terapia, en particular para uso en un método para tratar una enfermedad o trastorno por terapia de reemplazo de proteínas, ingeniería del genoma, reprogramación genética, e inmunoterapia; un método para incrementar la estabilidad del ARN en las células; un método para incrementar la expresión del ARN en las células; y un método para proporcionar un ARN con una estructura 5'-caperuza.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018056595 | 2018-03-15 | ||
| PCT/EP2019/056502 WO2019175356A1 (en) | 2018-03-15 | 2019-03-14 | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010871A true MX2020010871A (es) | 2020-11-09 |
Family
ID=65802103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010871A MX2020010871A (es) | 2018-03-15 | 2019-03-14 | Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210363172A1 (es) |
| EP (1) | EP3765477A1 (es) |
| JP (1) | JP7416705B2 (es) |
| KR (1) | KR20200143391A (es) |
| CN (1) | CN112119084A (es) |
| AU (1) | AU2019235424B2 (es) |
| BR (1) | BR112020026125A8 (es) |
| CA (1) | CA3093509A1 (es) |
| IL (1) | IL278058A (es) |
| MX (1) | MX2020010871A (es) |
| WO (1) | WO2019175356A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4104687T5 (da) | 2015-09-21 | 2024-07-22 | Trilink Biotechnologies Llc | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| PL432884A1 (pl) * | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| CN115803333A (zh) | 2020-07-02 | 2023-03-14 | 生命技术公司 | 三核苷酸帽类似物、其制备和用途 |
| EP4208549A1 (en) | 2020-09-04 | 2023-07-12 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| TW202245808A (zh) * | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| CN115197327A (zh) * | 2021-04-08 | 2022-10-18 | 上海细胞治疗集团有限公司 | Rna修饰嵌合蛋白及其应用 |
| WO2022228827A1 (en) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
| CN113603739B (zh) * | 2021-08-27 | 2024-08-23 | 上海兆维科技发展有限公司 | 一种加帽类似物及其应用 |
| JP7642260B2 (ja) * | 2022-02-28 | 2025-03-10 | ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 | Ｒｎａキャッピング用化合物及びその使用 |
| WO2023191342A1 (ko) * | 2022-03-31 | 2023-10-05 | 한미정밀화학 주식회사 | mRNA 캡 유사체 및 이의 용도 |
| WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
| CN117430652A (zh) * | 2022-07-22 | 2024-01-23 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的环状取代化合物及其应用 |
| WO2024161314A1 (en) * | 2023-01-31 | 2024-08-08 | Seqirus Inc. | Capping assay |
| WO2024193827A1 (en) | 2023-03-23 | 2024-09-26 | BioNTech SE | Stabilized nucleic acid compositions and methods for preparing, storing and using the same |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| WO2024236192A1 (en) | 2023-05-17 | 2024-11-21 | Institut Pasteur | Heterodimer of poxvirus a16 and g9 proteins as an immunogen |
| US20250026779A1 (en) * | 2023-06-29 | 2025-01-23 | Nutcracker Therapeutics, Inc. | Ethyl modified rna caps and methods of use |
| CN117534719B (zh) * | 2024-01-09 | 2024-05-14 | 北京悦康科创医药科技股份有限公司 | 一种c6'取代锁核酸修饰加帽类似物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CN104072561B (zh) * | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (en) * | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9522176B2 (en) * | 2013-10-22 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | MRNA therapy for phenylketonuria |
| DK4104687T5 (da) * | 2015-09-21 | 2024-07-22 | Trilink Biotechnologies Llc | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| US11866754B2 (en) * | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| EP3362460A1 (en) * | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
-
2019
- 2019-03-14 BR BR112020026125A patent/BR112020026125A8/pt unknown
- 2019-03-14 MX MX2020010871A patent/MX2020010871A/es unknown
- 2019-03-14 KR KR1020207029447A patent/KR20200143391A/ko not_active Application Discontinuation
- 2019-03-14 JP JP2020548976A patent/JP7416705B2/ja active Active
- 2019-03-14 EP EP19711343.4A patent/EP3765477A1/en active Pending
- 2019-03-14 WO PCT/EP2019/056502 patent/WO2019175356A1/en active Application Filing
- 2019-03-14 AU AU2019235424A patent/AU2019235424B2/en active Active
- 2019-03-14 CN CN201980032087.1A patent/CN112119084A/zh active Pending
- 2019-03-14 US US16/980,300 patent/US20210363172A1/en active Pending
- 2019-03-14 CA CA3093509A patent/CA3093509A1/en active Pending
-
2020
- 2020-10-14 IL IL278058A patent/IL278058A/en unknown
-
2021
- 2021-07-09 US US17/371,935 patent/US20210340170A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020026125A8 (pt) | 2022-10-18 |
| CA3093509A1 (en) | 2019-09-19 |
| JP2021515577A (ja) | 2021-06-24 |
| AU2019235424B2 (en) | 2023-12-21 |
| RU2020133704A (ru) | 2022-04-15 |
| KR20200143391A (ko) | 2020-12-23 |
| CN112119084A (zh) | 2020-12-22 |
| EP3765477A1 (en) | 2021-01-20 |
| IL278058A (en) | 2020-11-30 |
| US20210363172A1 (en) | 2021-11-25 |
| WO2019175356A1 (en) | 2019-09-19 |
| AU2019235424A1 (en) | 2020-09-03 |
| JP7416705B2 (ja) | 2024-01-17 |
| BR112020026125A2 (pt) | 2021-03-16 |
| US20210340170A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010871A (es) | Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia. | |
| MX2018011384A (es) | Arn de replicacion en trans. | |
| EA202090817A1 (ru) | Триспецифические белки и способы их применения | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| MX2018001040A (es) | Moleculas de acido nucleico artificiales. | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| PH12020551039A1 (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
| MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| EA202090034A1 (ru) | Способы модификации сплайсинга рнк | |
| SG10201903381TA (en) | Artificial nucleic acid molecules | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
| NZ725079A (en) | Transgene genetic tags and methods of use | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| BR112021025928A2 (pt) | Métodos de preparação de ácido bempedoico e composições do mesmo | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| AU2016277883A8 (en) | PD-1-CD28 fusion proteins and their use in medicine | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| PH12020551642A1 (en) | Aav compositions, methods of making and methods of use | |
| SA521422323B1 (ar) | Ii معززات هجين واستخداماتها في العلاج، ولا سيما في علاج الأمراض المرتبطة بالكولاجين من النوع | |
| MX2021011039A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. | |
| MX2022005670A (es) | Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BIONTECH SE |